CN118184750A - Immunogenic compositions of hepatitis C virus and uses thereof - Google Patents
Immunogenic compositions of hepatitis C virus and uses thereof Download PDFInfo
- Publication number
- CN118184750A CN118184750A CN202211596597.1A CN202211596597A CN118184750A CN 118184750 A CN118184750 A CN 118184750A CN 202211596597 A CN202211596597 A CN 202211596597A CN 118184750 A CN118184750 A CN 118184750A
- Authority
- CN
- China
- Prior art keywords
- hcv
- immunogenic composition
- virus
- pseudoparticles
- hepatitis
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 46
- 230000002163 immunogen Effects 0.000 title claims abstract description 38
- 241000711549 Hepacivirus C Species 0.000 title claims description 189
- 101710165315 Sialidase A Proteins 0.000 claims abstract description 46
- 229960005486 vaccine Drugs 0.000 claims abstract description 38
- 238000000034 method Methods 0.000 claims abstract description 17
- 230000028993 immune response Effects 0.000 claims abstract description 7
- 108090000288 Glycoproteins Proteins 0.000 claims description 30
- 102000003886 Glycoproteins Human genes 0.000 claims description 30
- 239000003937 drug carrier Substances 0.000 claims description 10
- 230000003612 virological effect Effects 0.000 claims description 9
- 238000002360 preparation method Methods 0.000 claims description 6
- SQVRNKJHWKZAKO-UHFFFAOYSA-N beta-N-Acetyl-D-neuraminic acid Natural products CC(=O)NC1C(O)CC(O)(C(O)=O)OC1C(O)C(O)CO SQVRNKJHWKZAKO-UHFFFAOYSA-N 0.000 claims description 4
- SQVRNKJHWKZAKO-OQPLDHBCSA-N sialic acid Chemical compound CC(=O)N[C@@H]1[C@@H](O)C[C@@](O)(C(O)=O)OC1[C@H](O)[C@H](O)CO SQVRNKJHWKZAKO-OQPLDHBCSA-N 0.000 claims description 4
- 239000000427 antigen Substances 0.000 claims description 3
- 108091007433 antigens Proteins 0.000 claims description 3
- 102000036639 antigens Human genes 0.000 claims description 3
- 238000002156 mixing Methods 0.000 claims description 2
- 210000004027 cell Anatomy 0.000 description 35
- 208000015181 infectious disease Diseases 0.000 description 27
- 241000699670 Mus sp. Species 0.000 description 26
- 230000001177 retroviral effect Effects 0.000 description 17
- 230000003472 neutralizing effect Effects 0.000 description 16
- 108090000623 proteins and genes Proteins 0.000 description 15
- 210000002966 serum Anatomy 0.000 description 13
- 102100038132 Endogenous retrovirus group K member 6 Pro protein Human genes 0.000 description 12
- 239000005090 green fluorescent protein Substances 0.000 description 11
- 238000006386 neutralization reaction Methods 0.000 description 11
- 239000002671 adjuvant Substances 0.000 description 10
- 241000714177 Murine leukemia virus Species 0.000 description 9
- 241000700605 Viruses Species 0.000 description 9
- 230000005847 immunogenicity Effects 0.000 description 9
- 239000002245 particle Substances 0.000 description 9
- 238000012360 testing method Methods 0.000 description 9
- 101710121417 Envelope glycoprotein Proteins 0.000 description 8
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 7
- 238000003556 assay Methods 0.000 description 7
- 238000006206 glycosylation reaction Methods 0.000 description 7
- 230000005764 inhibitory process Effects 0.000 description 7
- 238000004519 manufacturing process Methods 0.000 description 7
- 239000003550 marker Substances 0.000 description 7
- 230000037452 priming Effects 0.000 description 7
- 238000012546 transfer Methods 0.000 description 7
- 239000013598 vector Substances 0.000 description 7
- 101710132601 Capsid protein Proteins 0.000 description 6
- 108010067390 Viral Proteins Proteins 0.000 description 6
- 150000001875 compounds Chemical class 0.000 description 6
- PRAKJMSDJKAYCZ-UHFFFAOYSA-N dodecahydrosqualene Natural products CC(C)CCCC(C)CCCC(C)CCCCC(C)CCCC(C)CCCC(C)C PRAKJMSDJKAYCZ-UHFFFAOYSA-N 0.000 description 6
- 230000000694 effects Effects 0.000 description 6
- 239000013612 plasmid Substances 0.000 description 6
- 238000001890 transfection Methods 0.000 description 6
- 108010043121 Green Fluorescent Proteins Proteins 0.000 description 5
- 102000004144 Green Fluorescent Proteins Human genes 0.000 description 5
- 241001465754 Metazoa Species 0.000 description 5
- 230000013595 glycosylation Effects 0.000 description 5
- 230000002401 inhibitory effect Effects 0.000 description 5
- 239000011780 sodium chloride Substances 0.000 description 5
- 102100027221 CD81 antigen Human genes 0.000 description 4
- 101000914479 Homo sapiens CD81 antigen Proteins 0.000 description 4
- 241000725303 Human immunodeficiency virus Species 0.000 description 4
- 230000004988 N-glycosylation Effects 0.000 description 4
- 150000001413 amino acids Chemical class 0.000 description 4
- 239000013604 expression vector Substances 0.000 description 4
- 230000002458 infectious effect Effects 0.000 description 4
- 238000004806 packaging method and process Methods 0.000 description 4
- 230000001681 protective effect Effects 0.000 description 4
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 4
- 230000007502 viral entry Effects 0.000 description 4
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 3
- WVDDGKGOMKODPV-UHFFFAOYSA-N Benzyl alcohol Chemical compound OCC1=CC=CC=C1 WVDDGKGOMKODPV-UHFFFAOYSA-N 0.000 description 3
- 101710091045 Envelope protein Proteins 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 108010015899 Glycopeptides Proteins 0.000 description 3
- 102000002068 Glycopeptides Human genes 0.000 description 3
- 102000005744 Glycoside Hydrolases Human genes 0.000 description 3
- 108010031186 Glycoside Hydrolases Proteins 0.000 description 3
- 241000124008 Mammalia Species 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 101710188315 Protein X Proteins 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 230000003044 adaptive effect Effects 0.000 description 3
- 229940024606 amino acid Drugs 0.000 description 3
- 235000001014 amino acid Nutrition 0.000 description 3
- 239000002775 capsule Substances 0.000 description 3
- 238000004113 cell culture Methods 0.000 description 3
- 230000001413 cellular effect Effects 0.000 description 3
- 230000022811 deglycosylation Effects 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 238000009472 formulation Methods 0.000 description 3
- 208000006454 hepatitis Diseases 0.000 description 3
- 231100000283 hepatitis Toxicity 0.000 description 3
- 230000008348 humoral response Effects 0.000 description 3
- 238000000338 in vitro Methods 0.000 description 3
- 210000003292 kidney cell Anatomy 0.000 description 3
- 239000012528 membrane Substances 0.000 description 3
- 239000000546 pharmaceutical excipient Substances 0.000 description 3
- 235000018102 proteins Nutrition 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- 108020003175 receptors Proteins 0.000 description 3
- 102000005962 receptors Human genes 0.000 description 3
- 230000010076 replication Effects 0.000 description 3
- 125000005629 sialic acid group Chemical group 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 238000007920 subcutaneous administration Methods 0.000 description 3
- 239000006228 supernatant Substances 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- 231100000419 toxicity Toxicity 0.000 description 3
- 230000001988 toxicity Effects 0.000 description 3
- 241001430294 unidentified retrovirus Species 0.000 description 3
- YYGNTYWPHWGJRM-UHFFFAOYSA-N (6E,10E,14E,18E)-2,6,10,15,19,23-hexamethyltetracosa-2,6,10,14,18,22-hexaene Chemical compound CC(C)=CCCC(C)=CCCC(C)=CCCC=C(C)CCC=C(C)CCC=C(C)C YYGNTYWPHWGJRM-UHFFFAOYSA-N 0.000 description 2
- 229930183010 Amphotericin Natural products 0.000 description 2
- QGGFZZLFKABGNL-UHFFFAOYSA-N Amphotericin A Natural products OC1C(N)C(O)C(C)OC1OC1C=CC=CC=CC=CCCC=CC=CC(C)C(O)C(C)C(C)OC(=O)CC(O)CC(O)CCC(O)C(O)CC(O)CC(O)(CC(O)C2C(O)=O)OC2C1 QGGFZZLFKABGNL-UHFFFAOYSA-N 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 2
- 108020004414 DNA Proteins 0.000 description 2
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 2
- 241000588724 Escherichia coli Species 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 2
- 229930182555 Penicillin Natural products 0.000 description 2
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 2
- 108010076039 Polyproteins Proteins 0.000 description 2
- 101710172711 Structural protein Proteins 0.000 description 2
- BHEOSNUKNHRBNM-UHFFFAOYSA-N Tetramethylsqualene Natural products CC(=C)C(C)CCC(=C)C(C)CCC(C)=CCCC=C(C)CCC(C)C(=C)CCC(C)C(C)=C BHEOSNUKNHRBNM-UHFFFAOYSA-N 0.000 description 2
- 108091023045 Untranslated Region Proteins 0.000 description 2
- 229940009444 amphotericin Drugs 0.000 description 2
- APKFDSVGJQXUKY-INPOYWNPSA-N amphotericin B Chemical compound O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1/C=C/C=C/C=C/C=C/C=C/C=C/C=C/[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 APKFDSVGJQXUKY-INPOYWNPSA-N 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- AIYUHDOJVYHVIT-UHFFFAOYSA-M caesium chloride Chemical compound [Cl-].[Cs+] AIYUHDOJVYHVIT-UHFFFAOYSA-M 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 238000013461 design Methods 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 229960005542 ethidium bromide Drugs 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 239000012091 fetal bovine serum Substances 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 229920000159 gelatin Polymers 0.000 description 2
- 235000019322 gelatine Nutrition 0.000 description 2
- 150000004676 glycans Chemical group 0.000 description 2
- 229930004094 glycosylphosphatidylinositol Natural products 0.000 description 2
- 230000028996 humoral immune response Effects 0.000 description 2
- 230000003053 immunization Effects 0.000 description 2
- 238000002649 immunization Methods 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 239000003112 inhibitor Substances 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 230000003993 interaction Effects 0.000 description 2
- 239000007928 intraperitoneal injection Substances 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 2
- 238000001738 isopycnic centrifugation Methods 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 230000000873 masking effect Effects 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 239000002609 medium Substances 0.000 description 2
- OSWPMRLSEDHDFF-UHFFFAOYSA-N methyl salicylate Chemical compound COC(=O)C1=CC=CC=C1O OSWPMRLSEDHDFF-UHFFFAOYSA-N 0.000 description 2
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 2
- 230000003278 mimic effect Effects 0.000 description 2
- JXTPJDDICSTXJX-UHFFFAOYSA-N n-Triacontane Natural products CCCCCCCCCCCCCCCCCCCCCCCCCCCCCC JXTPJDDICSTXJX-UHFFFAOYSA-N 0.000 description 2
- 150000007523 nucleic acids Chemical group 0.000 description 2
- 239000002674 ointment Substances 0.000 description 2
- 229920001542 oligosaccharide Polymers 0.000 description 2
- 150000002482 oligosaccharides Chemical class 0.000 description 2
- 229940049954 penicillin Drugs 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 230000000644 propagated effect Effects 0.000 description 2
- 230000012846 protein folding Effects 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 230000003362 replicative effect Effects 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 230000035945 sensitivity Effects 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 229940032094 squalane Drugs 0.000 description 2
- 229940031439 squalene Drugs 0.000 description 2
- TUHBEKDERLKLEC-UHFFFAOYSA-N squalene Natural products CC(=CCCC(=CCCC(=CCCC=C(/C)CCC=C(/C)CC=C(C)C)C)C)C TUHBEKDERLKLEC-UHFFFAOYSA-N 0.000 description 2
- 229960005322 streptomycin Drugs 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 239000003826 tablet Substances 0.000 description 2
- 239000012096 transfection reagent Substances 0.000 description 2
- 230000010415 tropism Effects 0.000 description 2
- 230000007501 viral attachment Effects 0.000 description 2
- 210000000605 viral structure Anatomy 0.000 description 2
- 210000002845 virion Anatomy 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- 102000040650 (ribonucleotides)n+m Human genes 0.000 description 1
- NHBKXEKEPDILRR-UHFFFAOYSA-N 2,3-bis(butanoylsulfanyl)propyl butanoate Chemical compound CCCC(=O)OCC(SC(=O)CCC)CSC(=O)CCC NHBKXEKEPDILRR-UHFFFAOYSA-N 0.000 description 1
- BFSVOASYOCHEOV-UHFFFAOYSA-N 2-diethylaminoethanol Chemical compound CCN(CC)CCO BFSVOASYOCHEOV-UHFFFAOYSA-N 0.000 description 1
- 230000010773 Antigen Neutralization Effects 0.000 description 1
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 description 1
- 241000416162 Astragalus gummifer Species 0.000 description 1
- 238000011725 BALB/c mouse Methods 0.000 description 1
- 241001227713 Chiron Species 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 241000792859 Enema Species 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 206010016654 Fibrosis Diseases 0.000 description 1
- 241000710781 Flaviviridae Species 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 239000001828 Gelatine Substances 0.000 description 1
- 229920002683 Glycosaminoglycan Polymers 0.000 description 1
- 101710154606 Hemagglutinin Proteins 0.000 description 1
- 241000711557 Hepacivirus Species 0.000 description 1
- 101710125507 Integrase/recombinase Proteins 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 244000246386 Mentha pulegium Species 0.000 description 1
- 235000016257 Mentha pulegium Nutrition 0.000 description 1
- 235000004357 Mentha x piperita Nutrition 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- OVRNDRQMDRJTHS-RTRLPJTCSA-N N-acetyl-D-glucosamine Chemical group CC(=O)N[C@H]1C(O)O[C@H](CO)[C@@H](O)[C@@H]1O OVRNDRQMDRJTHS-RTRLPJTCSA-N 0.000 description 1
- 102000005348 Neuraminidase Human genes 0.000 description 1
- 108010006232 Neuraminidase Proteins 0.000 description 1
- 206010067482 No adverse event Diseases 0.000 description 1
- 101710144111 Non-structural protein 3 Proteins 0.000 description 1
- 101800001020 Non-structural protein 4A Proteins 0.000 description 1
- 101800001019 Non-structural protein 4B Proteins 0.000 description 1
- 108700026244 Open Reading Frames Proteins 0.000 description 1
- 101710093908 Outer capsid protein VP4 Proteins 0.000 description 1
- 101710135467 Outer capsid protein sigma-1 Proteins 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 101710176177 Protein A56 Proteins 0.000 description 1
- 101710185720 Putative ethidium bromide resistance protein Proteins 0.000 description 1
- 108091005487 SCARB1 Proteins 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- DWAQJAXMDSEUJJ-UHFFFAOYSA-M Sodium bisulfite Chemical compound [Na+].OS([O-])=O DWAQJAXMDSEUJJ-UHFFFAOYSA-M 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 108091027544 Subgenomic mRNA Proteins 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 230000024932 T cell mediated immunity Effects 0.000 description 1
- 229920001615 Tragacanth Polymers 0.000 description 1
- 206010058874 Viraemia Diseases 0.000 description 1
- 108010003533 Viral Envelope Proteins Proteins 0.000 description 1
- 108700022715 Viral Proteases Proteins 0.000 description 1
- 108070000030 Viral receptors Proteins 0.000 description 1
- 239000003070 absorption delaying agent Substances 0.000 description 1
- 150000001242 acetic acid derivatives Chemical class 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 239000011543 agarose gel Substances 0.000 description 1
- 238000000246 agarose gel electrophoresis Methods 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- 229940037003 alum Drugs 0.000 description 1
- 239000003708 ampul Substances 0.000 description 1
- 238000000540 analysis of variance Methods 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 230000000840 anti-viral effect Effects 0.000 description 1
- 230000005875 antibody response Effects 0.000 description 1
- 229940121375 antifungal agent Drugs 0.000 description 1
- 239000003429 antifungal agent Substances 0.000 description 1
- 239000004599 antimicrobial Substances 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 239000008135 aqueous vehicle Substances 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 229960001230 asparagine Drugs 0.000 description 1
- 235000009582 asparagine Nutrition 0.000 description 1
- 125000000613 asparagine group Chemical group N[C@@H](CC(N)=O)C(=O)* 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 235000019445 benzyl alcohol Nutrition 0.000 description 1
- 239000003833 bile salt Substances 0.000 description 1
- 229940093761 bile salts Drugs 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 230000007910 cell fusion Effects 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 239000002738 chelating agent Substances 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 230000007882 cirrhosis Effects 0.000 description 1
- 208000019425 cirrhosis of liver Diseases 0.000 description 1
- 150000001860 citric acid derivatives Chemical class 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- -1 coatings Substances 0.000 description 1
- 229940110456 cocoa butter Drugs 0.000 description 1
- 235000019868 cocoa butter Nutrition 0.000 description 1
- 230000019771 cognition Effects 0.000 description 1
- 229940075614 colloidal silicon dioxide Drugs 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- 239000007771 core particle Substances 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 230000007123 defense Effects 0.000 description 1
- 239000003599 detergent Substances 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 231100000676 disease causative agent Toxicity 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 239000002612 dispersion medium Substances 0.000 description 1
- 239000008298 dragée Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 229960001484 edetic acid Drugs 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 238000004520 electroporation Methods 0.000 description 1
- 239000007920 enema Substances 0.000 description 1
- 229940079360 enema for constipation Drugs 0.000 description 1
- 108700004025 env Genes Proteins 0.000 description 1
- 101150030339 env gene Proteins 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 239000012737 fresh medium Substances 0.000 description 1
- 238000002825 functional assay Methods 0.000 description 1
- IECPWNUMDGFDKC-MZJAQBGESA-N fusidic acid Chemical class O[C@@H]([C@@H]12)C[C@H]3\C(=C(/CCC=C(C)C)C(O)=O)[C@@H](OC(C)=O)C[C@]3(C)[C@@]2(C)CC[C@@H]2[C@]1(C)CC[C@@H](O)[C@H]2C IECPWNUMDGFDKC-MZJAQBGESA-N 0.000 description 1
- 108010027225 gag-pol Fusion Proteins Proteins 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 125000005456 glyceride group Chemical group 0.000 description 1
- 239000000185 hemagglutinin Substances 0.000 description 1
- 206010073071 hepatocellular carcinoma Diseases 0.000 description 1
- 231100000844 hepatocellular carcinoma Toxicity 0.000 description 1
- 210000003494 hepatocyte Anatomy 0.000 description 1
- 235000001050 hortel pimenta Nutrition 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 238000003119 immunoblot Methods 0.000 description 1
- 230000016784 immunoglobulin production Effects 0.000 description 1
- 239000002955 immunomodulating agent Substances 0.000 description 1
- 229940121354 immunomodulator Drugs 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 239000003701 inert diluent Substances 0.000 description 1
- 206010022000 influenza Diseases 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 239000007951 isotonicity adjuster Substances 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 238000010983 kinetics study Methods 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 230000021633 leukocyte mediated immunity Effects 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 208000019423 liver disease Diseases 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 239000002122 magnetic nanoparticle Substances 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 210000004962 mammalian cell Anatomy 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 210000004779 membrane envelope Anatomy 0.000 description 1
- STZCRXQWRGQSJD-GEEYTBSJSA-M methyl orange Chemical compound [Na+].C1=CC(N(C)C)=CC=C1\N=N\C1=CC=C(S([O-])(=O)=O)C=C1 STZCRXQWRGQSJD-GEEYTBSJSA-M 0.000 description 1
- 229940012189 methyl orange Drugs 0.000 description 1
- 239000004292 methyl p-hydroxybenzoate Substances 0.000 description 1
- 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 1
- 229960001047 methyl salicylate Drugs 0.000 description 1
- 229960002216 methylparaben Drugs 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 238000000520 microinjection Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 238000010172 mouse model Methods 0.000 description 1
- 239000002324 mouth wash Substances 0.000 description 1
- 229940051866 mouthwash Drugs 0.000 description 1
- 239000007922 nasal spray Substances 0.000 description 1
- 239000006218 nasal suppository Substances 0.000 description 1
- 239000000346 nonvolatile oil Substances 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 235000021317 phosphate Nutrition 0.000 description 1
- 150000003013 phosphoric acid derivatives Chemical class 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 108700004029 pol Genes Proteins 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 239000011148 porous material Substances 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 230000004853 protein function Effects 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 1
- 229940081974 saccharin Drugs 0.000 description 1
- 235000019204 saccharin Nutrition 0.000 description 1
- 239000000901 saccharin and its Na,K and Ca salt Substances 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 235000010267 sodium hydrogen sulphite Nutrition 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 238000011105 stabilization Methods 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000002511 suppository base Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 238000007910 systemic administration Methods 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 231100000057 systemic toxicity Toxicity 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 231100000027 toxicology Toxicity 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- 238000010361 transduction Methods 0.000 description 1
- 230000026683 transduction Effects 0.000 description 1
- 230000014599 transmission of virus Effects 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- 238000002255 vaccination Methods 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- 239000008215 water for injection Substances 0.000 description 1
- 230000004580 weight loss Effects 0.000 description 1
Landscapes
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
The present invention provides a method of preparing an immunogenic composition comprising treating HCV pseudoparticles with alpha 2-3,6,8,9 neuraminidase a to produce an immunogenic composition. Furthermore, the immunogenic composition is formulated as a vaccine for eliciting an immune response to HCV in a subject.
Description
Technical Field
The present invention provides an immunogenic composition comprising a Hepatitis C Virus (HCV) pseudoparticle treated with alpha 2-3,6,8,9 neuraminidase A. Furthermore, the present invention provides a use of an immunogenic composition comprising HCV pseudoparticles treated with alpha 2-3,6,8,9 neuraminidase a for the preparation of an HCV vaccine.
Background
Hepatitis C Virus (HCV) is the major causative agent of chronic liver disease, affecting about 1.7 hundred million people worldwide. Most (about 85%) HCV-infected individuals become chronically infected and are at risk of developing cirrhosis and hepatocellular carcinoma. HCV is a member of the flaviviridae family, which is a enveloped virus containing positive-strand genomic RNA. Based on the similarity of genomic sequences, HCV can be divided into six major genotypes and numerous subtypes. The HCV RNA genome comprises an open reading frame located at both the 5 'and 3' ends of the untranslated region (UTR). The positive-strand genomic RNA encodes a polyprotein of about 3010 amino acids, which is co-translated and translated by host and viral proteases into structural proteins (C, E, E2, and p 7) and non-structural proteins (NS 2, NS3, NS4A, NS4B, NS A and NS 5B).
Viral attachment and entry, which represents the first interaction of the virus with the host cell, is the primary goal of adaptive humoral responses. The viral proteins responsible for cell attachment and HCV entry are glycoproteins E1 and E2. Viral proteins are recognized as foreign bodies by the host's immune system and induce antibody production. A small fraction of these antibodies exhibit antiviral activity in vitro and are defined as virus neutralizing antibodies. Neutralizing antibody responses generally provide a first line of adaptive defense against infection by limiting viral transmission. Thus, expression of these glycoproteins has important applications in vaccine discovery and drug targeting. Thus, understanding the genotype and quasimial variation of the viral glycoprotein characteristics (quasispecies variation) is important for understanding the structure-function relationship of proteins.
The envelope glycoproteins E1 and E2 are natural targets for neutralizing antibodies. E2 is a preferred target for humoral and cell-mediated immune responses. Not surprisingly, most of the HCV sequence variation is concentrated in the highly variable region of E2. These regions are known to exhibit a high degree of variability, which can be used to distinguish HCV isolates of the same subtype from quasispecies confirmation (coexistence of different sequences in the same patient).
Glycans (glycans) associated with the viral envelope have a major role in masking neutralizing epitopes (epitopes) and regulating the overall immunogenicity of viral particles. Viral proteins are typically glycosylated by one of three different mechanisms. These processes not only differ among the cellular enzymes involved, but also produce different types of glycan structures. The resulting glycans are referred to as N-linked, O-linked, or glycosyl phosphatidylinositol (glycosylphosphatidylinositol, GPI) anchored. During N-linked glycosylation, the glycan chains are added to the viral protein through asparagine (asparagine) residues. N-linked glycosylation occurs at the site in the protein where the consensus amino acid sequence Asn-X-Ser/Thr is present. This is by far the most common means of glycosylation of viral proteins, which undergo N-linked glycosylation in a process similar to that which occurs on cellular glycoproteins.
Most glycosylation sites on HCV envelope glycoproteins are conserved, and certain glycans associated with these proteins have been shown to play an important role in protein folding and HCV entry. Such highly expressed glycosylation suggests that these glycans can limit the immunogenicity of HCV envelope proteins and limit the binding of certain antibodies to their epitopes on the surface of the virion, as observed in Human Immunodeficiency Virus (HIV) gp 120. According to reports, at least three glycans on E2 (E2N 1, E2N6 and E2N 11) reduce the sensitivity of HCVpp to antigen neutralization, and these glycans also reduce CD81 access to its E2 binding site. In contrast, there is no evidence that the N-linked glycans of E1 help mask the neutralizing epitope. These data suggest that glycans E2N1, E2N6 and E2N11 are able to access the binding site of CD81 and regulate binding of CD81 and neutralizing antibodies to E2. Briefly, this work points out that this region is the primary target for neutralizing antibodies, and HCV glycans help HCV to evade humoral immune responses.
The discovery of anti-HCV compounds and development of HCV vaccines is severely hampered by the lack of cell culture replication systems. The advent of subgenomic replicons that mimic the intracellular response leading to HCV genome replication has enabled the discovery of HCV protease and polymerase inhibitors since the late 1990 s, but failed to study HCV entry or entry inhibitors. Recently, the function of HCV E1E2 in cell attachment and entry (which summarises the whole HCV replication cycle) has been studied using a retroviral-based pseudoparticle (pseudoparticle, pp) assay, in which the infectivity of retroviral particles is conferred by HCV E1E2 envelope proteins. These new experimental systems have made rapid progress in cognition about how HCV glycoproteins E1 and E2 mediate receptor binding and viral entry. These systems facilitate the discovery of a range of viral receptors. This HCV pp assay is particularly useful in functional assays for HCV E1E2 derived from patients infected with different genotypes and virus subtypes, in profiling the role of the key E2 receptors CD81 and SR-B1 in viral entry, and in measuring the ability of antibodies and patient serum to neutralize infection of cells targeted by HCV pp.
Recently, infectious pseudoparticles assembled by expressing unmodified HCV envelope glycoproteins on retroviral core particles have been successfully produced. HCV pseudoparticles (HCV pseudoparticles, HCV pp) were made by transfection of 293T cells with three expression vectors encoding the E1E2 polyprotein, the retroviral core protein, and the packagable retroviral-derived genome with a marker gene, respectively. Surprisingly, infectious pseudoparticles can also be produced without any modification of the HCV envelope glycoprotein. The data accumulated on these pseudo particles strongly suggests that they may mimic the early steps of HCV infection. In fact, they exhibit preferential tropism for hepatocytes (tropism), and they can be neutralized by anti-E2 monoclonal antibodies as well as by serum specificity of HCV-infected patients. Thus, HCV pp represents the best tool currently available for studying functional HCV envelope glycoproteins and provides a model system for studying HCV cell entry. The development of HCV pp provides the possibility of HCV neutralization studies with confirmed HCV envelope glycoprotein sequences, and the use of HCV pp in neutralization studies has been validated. The above description has shown that the progressive appearance of relatively strong neutralization reactions is associated with a reduction in viremia.
Disclosure of Invention
The present invention provides a method of preparing an immunogenic composition comprising treating HCV pseudoparticles with alpha 2-3,6,8,9 neuraminidase a to produce an immunogenic composition. The present invention also provides an immunogenic composition comprising the HCV pseudoparticles treated with alpha 2-3,6,8,9 neuraminidase a. Furthermore, the present invention provides a use of an immunogenic composition comprising HCV pseudoparticles treated with alpha 2-3,6,8,9 neuraminidase a for the preparation of an HCV vaccine.
Viral attachment and entry, representing the first interaction of the virus with the host cell, is the primary goal of adaptive humoral responses. The viral proteins responsible for cell attachment and entry into HCV are glycoproteins E1 and E2. The present invention proposes deglycosylation of E1 and E2 by glycosidases (glycosidase), such as alpha 2-3,6,8,9 neuraminidase A (a broad specificity glycosidase which cleaves linear and branched non-reducing terminal sialic acid (SIALIC ACID) residues from glycoproteins, glycopeptides (glycopeptides) and oligosaccharides (oligosacccharides), which not only increases the sensitivity of detecting neutralizing antibody activity, but also initiates an immune response recognizing higher titres of E1 and E2 variants. To investigate the immunogenicity and protective capacity of HCV pseudoparticles treated with alpha 2-3,6,8,9 neuraminidase a, a mouse model was used. In the present invention, antisera from HCV Neura-A immunized mice were tested for their ability to inhibit HCV pp from entering huh7.5 cells (represented by the inhibition of infection rate of huh7.5 cells by HCV pp). The present invention shows that immunization with HCV Neura-A can induce an effective systemic humoral response with neutralizing activity compared to the control group, thus effectively inhibiting the infection rate of huh7.5 cells by HCV pp. The present invention points out that antisera from HCV Neura-A immunized mice can effectively neutralize HCV pp, thereby inhibiting HCV pp (carrying a complete and unmodified envelope glycoprotein of parental origin) from entering cells, and thus inhibiting huh7.5 cell infection. Accordingly, based on the results obtained from the neutralization studies described above, deglycosylation of HCV pp can be used to design an effective vaccine against HCV infection.
The strategy of the invention (hydrolysis of sialic acid residues of glycoprotein on HCV pp by alpha 2-3,6,8,9 neuraminidase a) opens up a new direction for vaccine design and can be used with other different vaccine strategies to facilitate development of anti-HCV vaccines.
The terms "a" or "an" are used herein to describe the elements and components of the present invention. This term is used for descriptive convenience only and gives a basic idea of the invention. The description should be read to include one or at least one and the singular also includes the plural unless it is clear that it is meant otherwise. The terms "a" and "an" when used in conjunction with the term "comprising" in the claims may mean one or more.
The term "or" as used in the claims means "and/or" unless explicitly indicated to the contrary, only other options are indicated or unless the other options are mutually exclusive.
The present invention provides a method of preparing an immunogenic composition comprising a viral antigen of Hepatitis C Virus (HCV), comprising: (a) Providing HCV pseudoparticles (HCV pseudoparticles, HCV pp); (b) Treating the HCV pseudoparticle with α2-3,6,8,9 neuraminidase a to remove sialic acid on the surface of the HCV pseudoparticle; and (c) isolating the HCV pseudoparticles produced in step (b) to produce the immunogenic composition.
In the present invention, the method for preparing HCV pseudo particles comprises: (1) Delivering an expression construct into the cell, wherein the expression construct comprises sequences encoding HCV glycoproteins E1 and E2, a retroviral core protein, and a retroviral derived genome; and (2) isolating HCV pseudoparticles produced by said cells.
In one embodiment, the sequences encoding HCV glycoproteins E1 and E2 comprise the sequences set forth in SEQ ID NO:1, and a sequence shown in 1.
In the method for producing HCV pseudoparticles, three independent expression constructs comprising three nucleic acid sequences encoding retroviral core, genome and hepatitis virus glycoprotein can be designed; alternatively, a construct may be designed which expresses a sequence comprising different nucleic acids. Such expression constructs are delivered into cells, thereby inducing the production of further replicating hepatitis virus pseudoparticles. In this case, the retroviral genome is modified to express hepatitis virus glycoproteins E1 and E2 in place of the retroviral Env gene (encoding the retroviral glycoprotein). However, the gene encoding the core protein of the retrovirus remains unchanged. Further, for example, additional genes encoding marker genes or immunomodulators may also be expressed from the genome.
In one embodiment, the cell is an in vitro cell. In a preferred embodiment, the cells comprise mammalian cells. In a more preferred embodiment, the cells comprise human embryonic kidney cells (human embryonic KIDNEY CELLS).
In the present invention, the delivery of the expression construct may be carried out by any standard method well known to those skilled in the art, such as transfection, electroporation, microinjection, transduction, cell fusion, DEAE glycosaminoglycan, calcium phosphate precipitation or the use of a gene gun.
In one embodiment, the expression construct further comprises a sequence for encoding a marker gene. In a preferred embodiment, the marker gene is a Green Fluorescent Protein (GFP) gene. The marker gene is intended for use in screening successfully transfected cells.
As used herein, the term "hepatitis C virus" (also known as hepatitis C virus, HEPATITIS C viruses, HCV) refers to any of a number of different genotypes and isolates of hepatitis C virus. Thus, "HCV" encompasses any of a variety of genotypes, subtypes or quasispecies of HCV, including, for example, genotypes 1, 2, 3, 4,6, 7, etc., and subtypes (e.g., 1a, 1b, 2a, 2b, 3a, 4c, etc.) and quasispecies. Representative HCV genotypes and isolates include: "Chiron" isolates HCV-1, H77, J6, con1, isolate 1, BK, EC1, EC10, HC-J2, HC-J5; HC-J6, HC-J7, HC-J8, HC-JT, HCT18, HCT27, HCV-476, HCV-KF, "Hunan", "Japanese", "Taiwan", TH, type 1a, type H77 type 1b, type 1c, type 1d, type 1e, type 1f, type 10, type 2a, type 2b, type 2c, type 2d, type 2f, type 3a, type 3b, type 3g, type 4a, type 4c, type 4d, type 4f, type 4H, type 4k, type 5a, type 6 and type 6 a.
The HCV genome encodes two membrane-associated envelope glycoproteins (E1 and E2), and they interact to form a non-covalent heterodimeric complex. HCV glycoproteins E1 and E2 are severely modified by N-linked glycosylation. The E1 protein is composed of 192 amino acids and contains 5 to 6N-glycosylation sites, depending on the HCV genotype. The E2 protein consists of 363 to 370 amino acids and contains 9-11N-glycosylation sites, depending on the HCV genotype.
In one embodiment, the viral antigen of HCV comprises glycoproteins E1 and E2 of HCV. The glycoproteins E1 and E2 of HCV are expressed on the surface of the HCV pseudoparticle. In a preferred embodiment, the HCV pseudoparticle has glycoproteins E1 and E2 of HCV.
As used herein, α2-3,6,8,9 neuraminidase a is a widely specific sialidase that cleaves linear and branched non-reducing terminal sialic acid residues from glycoproteins, glycopeptides and oligosaccharides. Thus, the present invention induces immunogenicity of HCV pseudoparticles by cleaving sialic acid on glycoproteins E1 and E2 of HCV pseudoparticles by α 2-3,6,8,9 neuraminidase a.
In another embodiment, in step (b), said HCV pseudoparticle is treated with said α2-3,6,8,9 neuraminidase a for 0.5 to 4 hours. In a preferred embodiment, in step (b), the HCV pseudoparticle is treated with α2-3,6,8,9 neuraminidase a for 0.5 to 3 hours. In a more preferred embodiment, in step (b), said HCV pseudoparticle is treated with said alpha 2-3,6,8,9 neuraminidase a for 1 to 2 hours.
In one embodiment, the method further comprises step (d) comprising mixing the HCV pseudoparticles of step (c) with a pharmaceutically acceptable carrier to produce an immunogenic composition. Still further, the HCV pseudoparticles of step (c) can be combined with the pharmaceutically acceptable carrier to produce an HCV vaccine.
The present invention also provides an immunogenic composition for eliciting an immune response to Hepatitis C Virus (HCV), wherein the immunogenic composition comprises an HCV pseudoparticle treated with alpha 2-3,6,8,9 neuraminidase a.
Furthermore, the immunogenic composition may optionally be combined with a suitable pharmaceutically acceptable carrier to enhance the protective effect of the HCV vaccine. In one embodiment, the HCV vaccine comprises the immunogenic composition and a pharmaceutically acceptable carrier.
The present invention further provides a method of eliciting an immune response to Hepatitis C Virus (HCV) in a subject comprising administering to the subject an effective dose of an HCV vaccine, wherein the HCV vaccine comprises an immunogenic composition, and the immunogenic composition comprises a 2-,6,8,9 neuraminidase a-treated HCV pseudoparticles.
In one embodiment, the subject is an animal, preferably a mammal, more preferably a human.
The present invention also provides a use of an immunogenic composition comprising HCV pseudoparticles treated with alpha 2-3, 6, 8, 9 neuraminidase a in the preparation of an HCV vaccine.
The vaccine of the present invention may be packaged into pharmaceutical or nutritional compositions or formulations along with additional active agents, carriers, vehicles, adjuvants, excipients or auxiliaries that will be appreciated by those skilled in the art after reading the present invention.
Adjuvants suitable for inclusion in the compositions of the present disclosure include those well known in the art, such as Freund's complete adjuvant (CFA), freund's incomplete adjuvant (IFA), squalene (squalene), squalane (squalane), alum and various oils, all of which are well known in the art and available from a variety of suppliers, such as North China (e.g., MF59 adjuvant).
In another embodiment, the vaccine comprises a pharmaceutically acceptable carrier. Thus, the immunogenic composition or vaccine of the invention further comprises a pharmaceutically acceptable carrier.
As used herein, the term "pharmaceutically acceptable carrier" includes solvents, dispersion media, coatings, antibacterial and antifungal agents, isotonic and absorption delaying agents, and the like, compatible with pharmaceutical administration. Supplementary active compounds may also be added to the vaccine. The vaccine is formulated to be compatible with its intended route of administration. Examples of routes of administration include parenteral, e.g., intravenous, intradermal, subcutaneous, oral (e.g., inhalation), transdermal (topical), transmucosal, and rectal administration. Solutions or suspensions for parenteral, intradermal, or subcutaneous application may include the following components: sterile diluents, such as water for injection, saline solution, fixed oils, polyethylene glycols, glycerol, propylene glycol or other synthetic solvents; antimicrobial agents, such as benzyl alcohol or methylparaben; antioxidants, such as ascorbic acid or sodium bisulfite; chelating agents such as ethylene diamine tetraacetic acid; buffers, such as acetates, citrates or phosphates, and agents for adjusting tonicity, such as sodium chloride or dextrose. The pH can be adjusted with acids or bases, for example hydrochloric acid or sodium hydroxide. Parenteral formulations may be enclosed in ampules, disposable syringes or multiple dose vials made of glass or plastic.
For parenteral administration, the immunogenic composition of the invention or vaccine thereof may be administered by intravenous, subcutaneous, intramuscular, intraperitoneal or intradermal injection, alone or in a composition further comprising a pharmaceutically acceptable carrier. For administration by injection, the immunogenic composition is preferably used in a solution of sterile aqueous vehicle, which may also contain other solutes, such as buffers or preservatives and sufficient pharmaceutically acceptable salts or glucose to render the solution isotonic. The immunogenic compositions of the invention may be obtained in the form of therapeutically acceptable salts well known in the art.
The vaccine may also be administered orally. Oral compositions typically include an inert diluent or an edible carrier. For the purposes of oral therapeutic administration, the active compounds may be combined with excipients and used in the form of tablets, dragees or capsules, such as gelatine capsules. Oral compositions may also be prepared using a fluid carrier for use as a mouthwash. Pharmaceutically compatible binding or adjuvant materials may be included as part of the composition. Tablets, pills, capsules, troches and the like may contain any of the following ingredients or compounds of similar nature: binders, such as microcrystalline cellulose, gum tragacanth or gelatin; excipients, for example starch or lactose; disintegrants, for example alginic acid, primogel or corn starch; lubricants, such as magnesium stearate or Sterotes; glidants, such as colloidal silicon dioxide; sweeteners, such as sucrose or saccharin; or a flavoring agent such as peppermint, methyl salicylate, or orange flavoring.
Systemic administration may also be transmucosal or transdermal. For transmucosal or transdermal administration, penetrants appropriate to the barrier to be permeated are used in the formulation. Such penetrants are generally known in the art, and include, for example, detergents, bile salts, and fusidic acid derivatives for transmucosal administration. Transmucosal administration can be accomplished through the use of nasal sprays or suppositories. For transdermal administration, the active compounds are formulated into ointments, salves, gels or creams as known in the art. The compounds may also be formulated in the form of suppositories (e.g., with conventional suppository bases such as cocoa butter and other glycerides) or retention enemas for rectal delivery.
It is advantageous to formulate oral or parenteral compositions in dosage unit form for ease of administration and uniformity of dosage. Dosage unit form as used herein refers to physically discrete units suitable as unitary dosages for the subject to be treated; each unit contains a predetermined amount of active compound calculated to produce the desired therapeutic effect and associated with the desired pharmaceutical carrier.
It will be further appreciated that the amount of the immunogenic composition or vaccine of the invention that can be used to treat or prevent HCV will vary depending on the route of administration, the nature of the disorder being treated, and the age and condition of the subject, and will ultimately be at the discretion of the attendant physician.
The concentration of immunogen contained in the vaccine is that amount which will elicit an immune response without significant adverse side effects. The amount will vary depending on the immunogen used and the type and amount of adjuvant contained in the vaccine. Typically, the vaccine will comprise the immunogen in an amount of from about 0.1 to about 1000 μg/ml, preferably from about 0.2 to about 100 μg/ml, more preferably from about 0.5 μg to about 10 μg/ml. Following initial vaccination, the vaccinated subject may receive one or several booster immunizations at appropriate intervals thereafter.
Those of skill in the art will appreciate that the present disclosure extends from treatment to prevent established infections or symptoms. The immunogenic compositions and vaccines of the present invention may be administered as therapeutic or prophylactic. Treatment is preferably initiated prior to or at the time of infection or at the time of exposure of the mammal to HCV infection and continued until the virus is no longer present. However, treatment may also be initiated after infection, after exposure of the mammal to HCV infection, or after symptoms of the established infection.
Thus, when the immunogenic compositions of the invention are administered to a subject in need thereof, an immune response (e.g., a cellular immune response) is elicited in the subject against one or more HCV genotypes.
Drawings
FIG. 1 shows a transfer vector construct for producing HCV pseudo particles.
FIG. 2 shows the electrophoretic analysis of purified plasmids in 0.7% agarose gel. The left-hand numerical value of the figure is the Molecular Weight (MW) label (in kb). M: marking (marker).A:phCMV-cE1E2(1a),MW = 7,754 bp.B:CMV-Gag-Pol MLV,MW = 11,984 bp.C:CMV-GFP MLV,MW = 6,309 bp.
FIG. 3 shows HEK293T post-transfection with intense green fluorescence.
FIG. 4 shows the neutralizing capacity of serum from HCV Neura-A immunized mice. Serum from HCV Neura-A immunized mice showed potent neutralizing activity (suggesting infection inhibition performance) compared to mice of the control group (saline injected). However, no significant inhibition was observed with serum from HCV pp immunized mice. Female Balb/c mice (control/experimental group number of groups of 10) 6-8 weeks old were immunized by intraperitoneal injection. Each mouse was inoculated with 5. Mu.L of physiological saline (for control group), 5. Mu.g of HCV pp or HCV Neura-A with Freund's adjuvant. Priming (priming) on day 1, boosting (boosting) on days 14 and 28; blood was collected on days 1, 14, 28 and 42. Data are expressed as mean ± standard error of mean, number 10.* Representing p < <0.05, ns represents no significant statistical difference from the control group.
Detailed Description
This invention may be embodied in many different forms and should not be construed as limited to the embodiments set forth herein. The described embodiments should not be used to limit the scope of the invention as described in the claims.
Materials and methods
I. Reagent(s)
Alpha 2-3,6,8,9 neuraminidase A (Neura-A) was purchased from NEW ENGLAND Biolabs (Ipswich, mass., USA). DMEM, fetal bovine serum, streptomycin and penicillin were purchased from GIBCO BRL (Gaithersburg, md, USA). Freund's complete/incomplete adjuvant was purchased from SIGMA ALDRICH, inc. (St. Louis, mo, USA). Mag4C LV kit was purchased from OZ Biosciences (Av. De Luminy, marseille, france). Macrosep advanced centrifuge apparatus, MWCO 100K, available from Pall Corporation (Port Washington, new York, USA). TransIT-LT1 transfection reagent was purchased from Mirus, inc. (Madison, wis., USA).
II cell culture
HEK293T and huh7.5 cells were cultured in DMEM medium (Gibco) supplemented with 10% (v/v) fetal bovine serum, 10U/mL penicillin, 10 μg/mL streptomycin and 0.25 μg/mL amphotericin (amphotericin) B and at 37 ℃ and 5% CO 2.
III production of HCV pseudo particle (HCV pp)
The E1E2 and retroviral expression constructs (fig. 1) used to produce HCV pseudoparticles (HCV pp) were provided by b. Bartosh doctor and f.l. Cosset doctor (INSERM U758, lyon, france) friends. HCV pp is prepared as follows (including HCV E1E2 expression, packaging and transfer vectors).
III.1 packaging of transfer vector constructs
FIG. 1 shows CMV-Gag-Pol murine leukemia virus (murine leukemia virus, MLV) packaging constructs for encoding the MLV Gag and Pol genes, as well as MLV-GFP plasmids for encoding MLV-based transfer vectors containing CMV-GFP internal transcription units. The system exploits two well-documented properties of retroviruses, namely the ability to incorporate exogenous glycoproteins and the ability to integrate and express marker genes from non-replicating viral particles, resulting in a specific, rapid and reliable in vitro infection assay based on unmodified E1 and E2 HCV glycoproteins exhibited by pseudoparticles. HCV pseudoparticles (HCV pp) are generated by assembling these full-length, unmodified E1 and E2 glycoproteins onto an MLV-derived retroviral core protein. Retroviruses were chosen as the platform for assembly of HCV pp because their core can contain a variety of different cellular and viral glycoproteins, and because they can readily package and integrate gene markers into the DNA of infected cells. Immunoblot analysis of transfected cells showed that the structural components of the pseudo-particles were easily detected at the expected molecular weight; namely, E1 is about 30 kD, E2 is about 60 kD, and VSV-G is about 60 kD. Thus, this system describes for the first time the formation of highly infectious HCV pseudoparticles, and these pseudoparticles may share early cell entry properties with the parent HCV.
III.2 preparation and purification of plasmids
Plasmids phCMV-cE1E2 (1 a), CMV-Gag-Pol MLV and CMV-GFP MLV were propagated in E.coli, isolated and purified by equilibrium centrifugation in cesium chloride (CsCl) -ethidium bromide gradients (for production of HCV pp by transfection into HEK293T cells).
III.3 production of naturally complete glycosylated pseudoparticles (HCV pp)
To produce HCV pp with native fully glycosylated E1E2, human embryonic kidney cells (HEK 293T), i.e., E1E2 glycoprotein (phCMV-cE 1E2 (1 a)), retroviral core protein (CMV-Gag-Pol MLV) and a packagable GFP-containing retroviral transfer vector (CMV-GFP MLV) were transfected by an expression vector for encoding the viral component. The sequences published by researchers on the gene bank (Genbank) (Genbank accession number AY 734972.1) for encoding E1 and E2 glycoproteins from HCV type 1a are SEQ ID NO:1. thus, the invention will have the sequence of SEQ ID NO:1 into an expression vector for expression of glycoproteins E1 and E2.
Briefly, DNA of Gag-Pol packaging construct (12 μg), transfer vector construct (12 μg) and glycoprotein expression construct (4 μg) was transfected into 2.5×10 6 HEK293T cells seeded on a 10 cm plate the previous day, using TransIT-LT1 transfection reagent from Mirus, inc. (Madison, wis., USA) according to the manufacturer's guidelines. 16 hours after transfection, the medium was changed (8 mL/plate). 48 hours after transfection, the supernatant containing the pseudoparticles was collected, filtered through a 0.45 μm pore size membrane (for infection of huh7.5 cells) and concentrated 20-fold using a Macrosep Advance centrifugation device, MWCO 100K.
Test vaccine production (HCV pp and HCV Neura-A)
For the test vaccine HCV Neura-A, alpha 2-3,6,8,9 neuraminidase a was used to cleave off native fully glycosylated HCV pp, which was performed as follows: (1) 10 μg HCV pp and water were mixed in a total reaction volume of 90 μl; (2) 10 mu L GlycoBuffer (10X) was added to give a total reaction volume of 100. Mu.L; (3) adding 10. Mu.L of alpha.2-3,6,8,9 neuraminidase A; and (4) incubation at 37℃for 1 hour.
For control experiments using native fully glycosylated HCV pp as vaccine, HCV pp was treated in the same way as described above, but without the addition of α2-3, 6, 8, 9 neuraminidase a.
Finally, the product was purified by a Mag4C LV magnetic nanoparticle kit from OZ Biosciences according to the manufacturer's guidelines procedure.
V. testing vaccine (HCV pp and HCV Neura-A) for immunogenicity
Glycosylation is known to affect protein folding and protein function. Glycans associated with viral membranes also play an important role in masking neutralizing epitopes and regulating the overall immunogenicity of viral particles. Such high degree of glycosylation on E1E2 suggests that these glycans can limit the immunogenicity of HCV envelope proteins and limit the binding of certain antibodies to epitopes on their virion surfaces, as observed for Human Immunodeficiency Virus (HIV) gp 120.
Furthermore, previous studies on influenza demonstrated that the mono-glycosylated hemagglutinin showed a similar secondary structure and better binding affinity to the host receptor compared to the fully glycosylated counterpart. Furthermore, asn of a single GlcNAc residue is the smallest component of N-glycans required for glycoprotein folding and stabilization.
To investigate the effect of deglycosylation with alpha 2-3,6,8,9 neuraminidase a on HCV pp, BALB/c mice were immunized with saline (as control), HCV pp or HCV Neura-A.
V.1 in vivo animal studies
Female BALB/c,6-8 week old, purchased from BioLASCO (BioLASCO, taibei, taiwan, china) and maintained under conditions consistent with relevant guidelines and regulations for the care and use of laboratory animals at the university of Chinese medicine in Taiwan, china.
30 Mice were randomly and equally divided into 3 groups for evaluation of immunogenicity and toxicity of the test vaccines HCV pp and HCV Neura-A.
On days 1, 14 and 28, mice were given antisera by intraperitoneal injection of 5 μg HCV pp、HCVNeura-A or saline (for control) and an equal volume of freund's adjuvant. Antisera were taken on days 1, 14, 28 and 42. All serum samples were stored at-80 ℃ after collection.
Antisera from each group were compared and their ability to bind to native fully glycosylated HCV pp (shown by infection inhibitory activity) was analyzed using a neutralization assay.
V.2. neutralization assay
To evaluate the neutralizing activity of serum from immunized mice, serum from control group, HCV pp immunized mice and HCV Neura-A immunized mice will be used for the study.
Huh7.5 cells were pre-seeded into 12 well cell culture plates at a density of 1 x 10 5 per well. The next day, HCV pp supernatants (225 μl/well) were combined with the samples from the control group, HCV pp immunized mice and HCV Neura-A at 1: an equal volume of antisera after 2 dilutions was incubated for 1 hour at 37 ℃. The mixture was then added to each well. After incubation at 37 ℃ for 3 hours, the supernatant was replaced with fresh medium and incubated at 37 ℃ for 72 hours. The entry of HCV was confirmed by the percentage of GFP positive cells measured by a Countess II FL automated cell counter (ThermoFisher Scientific, USA).
VI statistical analysis
Data are expressed as mean ± standard error. Evaluation of statistical significance was confirmed by single factor variance analysis (ANOVA) and p-values were calculated using SPSS 16.0 software. p values less than 0.05 are considered statistically significant.
Results
Preparation and purification of plasmids
Plasmids phCMV-cE1E2 (1 a), CMV-Gag-Pol MLV and CMV-GFP MLV were propagated in E.coli, isolated and purified by equilibrium centrifugation in a CsCl-ethidium bromide gradient. Purity was checked by 0.7% agarose gel electrophoresis as shown in fig. 2.
Production of naturally complete glycosylated pseudoparticles (HCV pp)
To produce HCV pp with native fully glycosylated E1E2, the expression vector encoding the viral component was transfected into human embryonic kidney cells (HEK 293T), i.e., the E1E2 glycoprotein, the retroviral core protein, and a packagable GFP-containing retroviral transfer vector. Finally, successfully transfected cells with intense green fluorescence were generated (fig. 3).
Immunogenicity in Balb/c mice: protective ability of serum of HCV Neura-A immunized mice
To test the function of the test vaccines HCV pp and HCV Neura-A, neutralization assays were used to test all samples from the control group, HCV pp immunized mice and HCV Neura-A immunized mice for their ability to inhibit HCV pp infection with huh7.5 cells.
The main correlation of the efficacy of the test vaccine is the extent of neutralizing antibodies (NtAb), which are shown as infection-inhibiting activity in the neutralization assay using huh7.5 cells. The neutralizing activity of the serum of saline-immunized mice and the serum of HCV pp -immunized mice or HCV Neura-A -immunized mice was compared with each other. Vaccine toxicity was also assessed together.
The present inventors found that all 10 serum samples from HCV Neura-A immunized mice significantly inhibited the infectious activity of HCV pp, suggesting an effective neutralizing capacity as well as protective capacity, compared to the control group.
For HCV Neura-A immunized mice, the extent of infection inhibition correlates with priming and boosting time. As shown in fig. 4, a significant degree of inhibition of infection was detected 14 days after priming (74.69% ± 12.53) compared to the mice of the control group. After priming on day 1 and boosting on day 14, the neutralization activity reached a high level (53.87% ± 7.96) on day 28 and remained high (49.09±8.17) to day 42 (second boosting on day 28), suggesting that the neutralization activity (and specific protection against HCV pp infection NtAb) increased in the same manner.
However, no significant inhibition of infection was observed for serum from naturally fully glycosylated HCV pp immunized mice. As shown in fig. 4, the infection inhibition rate detected 14 days after priming was lower (96.47% ± 15.26) than that of the mice in the control group. The neutralization activity was boosted on days 1 and 14 after priming, kept low on day 28 (95.57% ± 14.17), and remained low (96.43% ± 15.69) to day 42 (second boosting on day 28).
Toxicity of
The test vaccine was subjected to a 6 week toxicology kinetics study. As described above, a total of 30 mice were randomly allocated to 3 groups (10 animals/group), including saline (control group), HCV pp groups, and HCV Neura-A groups, and were intraperitoneally injected on days 1, 14, and 28.
Under the conditions of the present invention, no morbidity or mortality was found; no adverse reactions, weight loss or other significant systemic toxicity were found in clinical observations during dosing and at the end of the 2-week recovery period for all animals.
Those skilled in the art will understand the concepts described above as descriptions of methods for delivering deposited application information. Those skilled in the art will recognize that these are merely illustrative and that many equivalents are possible.
Claims (7)
1. A method of preparing an immunogenic composition comprising a viral antigen of Hepatitis C Virus (HCV), comprising: (a) providing HCV pseudoparticles; (b) Treating the HCV pseudoparticle with α2-3,6,8,9 neuraminidase a to remove sialic acid on the surface of the HCV pseudoparticle; and (c) isolating the HCV pseudoparticles produced in step (b) to produce the immunogenic composition.
2. The method of claim 1, wherein the HCV pseudoparticle has glycoproteins E1 and E2 of HCV.
3. The method of claim 1, wherein in step (b), the HCV pseudoparticle is treated with the alpha 2-3,6,8,9 neuraminidase a for 0.5 to 4 hours.
4. The method of claim 1, further comprising step (d) comprising mixing the HCV pseudoparticles of step (c) with a pharmaceutically acceptable carrier to produce the immunogenic composition.
5. An immunogenic composition for eliciting an immune response to hepatitis C virus, wherein the immunogenic composition is prepared by the method of claim 1.
6. Use of an immunogenic composition for the preparation of a hepatitis C virus vaccine, wherein the immunogenic composition is prepared by the method of claim 1.
7. The use according to claim 6, wherein the hepatitis C virus vaccine is in a dosage range of 0.1-1000 μg/ml.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202211596597.1A CN118184750A (en) | 2022-12-12 | 2022-12-12 | Immunogenic compositions of hepatitis C virus and uses thereof |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202211596597.1A CN118184750A (en) | 2022-12-12 | 2022-12-12 | Immunogenic compositions of hepatitis C virus and uses thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
CN118184750A true CN118184750A (en) | 2024-06-14 |
Family
ID=91401102
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202211596597.1A Pending CN118184750A (en) | 2022-12-12 | 2022-12-12 | Immunogenic compositions of hepatitis C virus and uses thereof |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN118184750A (en) |
-
2022
- 2022-12-12 CN CN202211596597.1A patent/CN118184750A/en active Pending
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Haffar et al. | Human immunodeficiency virus-like, nonreplicating, gag-env particles assemble in a recombinant vaccinia virus expression system | |
RU2274643C2 (en) | Isolated envelope hcv protein, method for its preparing and drug, vaccine, pharmaceutical composition (variants) comprising thereof | |
KR101500017B1 (en) | recombinant HCV E2 glycoprotein | |
US8716013B2 (en) | Recombinant lentiviral vector for expression of a flaviviridae protein and applications thereof as a vaccine | |
CZ266798A3 (en) | Synthetic polynucleotide containing dna sequences encoding hiv proteins | |
EP2794637B1 (en) | Vesicular stomatitis virus for prime boost vaccines | |
US7847085B2 (en) | Recombinant HIV-1 gp120 immunogen with three different V3 loops from viruses of different clades | |
FRANCHINI et al. | Highly attenuated HTLV type I env poxvirus vaccines induce protection against a cell-associated HTLV type I challenge in rabbits | |
SK18993A3 (en) | Vaccine and treatment method of hiv infection | |
US9884109B2 (en) | Compositions and methods | |
EP1461424B1 (en) | Generation of virus-like particles and demonstration of lipid rafts as sites of filovirus entry and budding | |
US20230149537A1 (en) | Vaccines, adjuvants, and methods of generating an immune response | |
EP2020444B1 (en) | Defective non-integrative lentiviral transfer vectors for vaccines | |
TWI844199B (en) | Immunogenic compositions of hepatitis c virus and uses thereof | |
CN118184750A (en) | Immunogenic compositions of hepatitis C virus and uses thereof | |
US20240189421A1 (en) | Immunogenic compositions of hepatitis c virus and uses thereof | |
JPH02203793A (en) | Vaccine containing polypeptide derived from envelope gene of human immunodefficiency virus type 1 | |
CN113248608B (en) | Chikungunya virus E2 protein rabbit monoclonal antibody and application thereof | |
TW202423478A (en) | Immunogenic compositions of hepatitis c virus and uses thereof | |
US9732121B2 (en) | Rational vaccine design for hepatitis C virus | |
WO2004072096A2 (en) | Peptides binding gp120 of hiv-1 | |
Enose et al. | Restriction of viral population by intravaginal infection of simian immunodeficiency viruses in macaque monkeys | |
US20030124146A1 (en) | Recombinant Rhabdoviruses as live-viral vaccines | |
CN113248607B (en) | Chikungunya virus E2 protein rabbit monoclonal antibody and application thereof in developing therapeutic antibody | |
US20030091590A1 (en) | Recombinant rhabdoviruses as live-viral vaccines |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination |